BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 12670915)

  • 1. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
    Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB
    Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Id2 mRNA in neuroblastoma and normal ganglion.
    Sato Y; Kobayashi Y; Sasaki H; Toyama T; Kondo S; Kiriyama M; Fujii Y
    Eur J Surg Oncol; 2003 Apr; 29(3):284-7. PubMed ID: 12657241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
    Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
    Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
    Shohet JM; Hicks MJ; Plon SE; Burlingame SM; Stuart S; Chen SY; Brenner MK; Nuchtern JG
    Cancer Res; 2002 Feb; 62(4):1123-8. PubMed ID: 11861392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.
    Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF
    Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.